Somapacitan, a once-weekly reversible albumin-binding growth hormone (GH) derivative, is well tolerated and convenient in adults with GH deficiency (AGHD): Results from a 26-week randomised, controlled phase 3 trial

Authors
Category Primary study
ConferenceHormone Research in Paediatrics
Year 2016
This article has no abstract
Epistemonikos ID: 91a68326add4f6c788bfb4c8b68f3634db6d194d
First added on: Apr 29, 2026